{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [],
  "GeneralNote": [],
  "OtherAbstract": [],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "18220028",
  "DateCompleted": {
    "Year": "2008",
    "Month": "02",
    "Day": "21"
  },
  "DateRevised": {
    "Year": "2015",
    "Month": "11",
    "Day": "19"
  },
  "Article": {
    "ArticleDate": [],
    "Language": [
      "rus"
    ],
    "ELocationID": [],
    "Journal": {
      "ISSN": "0040-3660",
      "JournalIssue": {
        "Volume": "79",
        "Issue": "12",
        "PubDate": {
          "Year": "2007"
        }
      },
      "Title": "Terapevticheskii arkhiv",
      "ISOAbbreviation": "Ter Arkh"
    },
    "ArticleTitle": "[The course of coronary heart disease and quality of life in patients with anxiety of different degree].",
    "Pagination": {
      "StartPage": "35",
      "EndPage": "38",
      "MedlinePgn": "35-8"
    },
    "Abstract": {
      "AbstractText": [
        "To study an emotional status and quality of life (QL) in patients with coronary heart disease (CHD) and anxiety, to evaluate efficacy of anxiolytic drug lorazepam (lorafen) in such patients.",
        "Anxiety in 277 CHD patients was assessed by hospital scale of anxiety and depression, depression--by Beck's questionnaire, QL--by Seattle questionnaire.",
        "CHD patients with clinically significant anxiety had more serious vegetative disorders, worse QL and prognosis. Lorazepam treatment improved both emotional state of the patients and QL.",
        "High prevalence of anxious disorders in CHD patients deteriorating QL and prognosis dictates the necessity of detecting and treating anxiety in CHD patients."
      ]
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [],
        "LastName": "Ibatov",
        "ForeName": "A D",
        "Initials": "AD"
      }
    ],
    "PublicationTypeList": [
      "Comparative Study",
      "English Abstract",
      "Journal Article"
    ]
  },
  "MedlineJournalInfo": {
    "Country": "Russia (Federation)",
    "MedlineTA": "Ter Arkh",
    "NlmUniqueID": "2984818R",
    "ISSNLinking": "0040-3660"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Anti-Anxiety Agents"
    },
    {
      "RegistryNumber": "O26FZP769L",
      "NameOfSubstance": "Lorazepam"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Anti-Anxiety Agents"
    },
    {
      "QualifierName": [
        "drug therapy",
        "etiology",
        "psychology"
      ],
      "DescriptorName": "Anxiety"
    },
    {
      "QualifierName": [
        "complications",
        "physiopathology",
        "psychology"
      ],
      "DescriptorName": "Coronary Disease"
    },
    {
      "QualifierName": [
        "physiology"
      ],
      "DescriptorName": "Emotions"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [
        "therapeutic use"
      ],
      "DescriptorName": "Lorazepam"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Prognosis"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Quality of Life"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Severity of Illness Index"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Surveys and Questionnaires"
    }
  ]
}